Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo GalluzziCaryl and Israel Englander Institute for Precision Medicine, New York City, New York, USAIlio VitaleCandiolo Cancer Institute, FPO - IRCCS, Candiolo, ItalySarah H. WarrenNanoString Technologies, Seattle, Washington, USASandy AdjemianDepartment of Biomedical Molecular Biology (DBMB), Ghent University, Ghent, BelgiumPatrizia AgostinisCell Death Research & Therapy (CDRT) Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumAitziber Buqué MartinezDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USATimothy A. ChanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USAGeorge CoukosLudwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne, SwitzerlandSandra DemariaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York City, New York, USAÉric DeutschDepartment of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, FranceDobrin DraganovCalidi Biotherapeutics, San Diego, California, USARichard L. EdelsonComprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USASilvia C. FormentiDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USAJitka FučíkováDepartment of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech RepublicLucia GabrieleDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, ItalyUdo S. GaiplUniversitätsklinikum Erlangen, Erlangen, GermanySofia R. GameiroLaboratory of Tumor Immunology and Biology, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USAAbhishek D. GargCell Death Research & Therapy (CDRT) Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumEncouse B. GoldenDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USAJian HaniRepertoire, Inc, Huntsville, Alabama, USAKevin J. HarringtonDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UKAkseli HemminkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandJames W. HodgeLaboratory of Tumor Immunology and Biology, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USADewan Md Sakib HossainMerck & Co. Inc, Kenilworth, New Jersey, USATim IllidgeUniversity of Manchester, NIHR Manchester Biomedical Research Centre, Christie Hospital, Manchester, UKMichael KarinDepartment of Pharmacology and Pathology, University of California at San Diego (UCSD) School of Medicine, La Jolla, California, USAHoward L. KaufmanDivision of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USAOliver KeppEquipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, FranceGuido KroemerEquipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, FranceJuan José LasarteProgram of Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), University of Navarra, Pamplona, SpainSherene LoiDepartment of Oncology, University of Melbourne, Parkville, Victoria, AustraliaMichael T. LotzeDepartment of Bioengineering, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USAGwenola ManicCandiolo Cancer Institute, FPO - IRCCS, Candiolo, ItalyTaha MerghoubLudwig Collaborative and Swim Across America Laboratory, MSKCC, New York City, New York, USAAlan MelcherThe Institute of Cancer Research, London, UKKaren MossmanMcMaster University, Hamilton, Ontario, CanadaFelipe PrósperHematology and Cell Therapy, Clinica Universidad de Navarra, Pamplona, SpainØystein RekdalDepartment of Medical Biology, University of Tromsø, Tromsø, NorwayMaría RescignoHumanitas Clinical and Research Center – IRCCS, Rozzano, ItalyChiara RigantiDepartment of Oncology, University of Torino, Torino, ItalyAntonella SistiguIstituto di Patologia Generale, Università Cattolica del Sacro Cuore, Rome, ItalyMark J. SmythImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, AustraliaRadek ŠpíšekDepartment of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech RepublicJohn StaggCentre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Quebec City, CanadaBryan E. StraussCentro de Investigação Translacional em Oncologia/LIM24, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo, BrasilDaolin TangDepartment of Surgery, UT Southwestern Medical Center, Dallas, Texas, USAKazuki TatsunoDepartment of Dermatology, Yale School of Medicine, New Haven, Connecticut, USAStefaan Van GoolImmun-Onkologisches Zentrum Köln, Cologne, GermanyPeter VandenabeeleDepartment of Biomedical Molecular Biology (DBMB), Ghent University, Ghent, BelgiumTakahiro YamazakiDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USADmitriy ZamarinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USALaurence ZitvogelCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FranceAlessandra CesanoESSA Pharmaceuticals, South San Francisco, California, USAFrancesco M. MarincolaRefuge Biotechnologies, Menlo Park, California, USA
2020en
ABI
Аннотация
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0